GlassScriptPhysician profile
David A Stewart
NPI 1730160144
$10,862.72
in general payments reported to CMS, 2019-2025
28 companies · $238 in 2025
The $238 reported for 2025 was more than what 84% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,174 · 2020: $298 · 2021: $2,094 · 2022: $388 · 2023: $391 · 2024: $280 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,952.74 | 2019-2025 | Relistor |
| Redhill Biopharma INC. | $1,711.58 | 2021 | |
| Kaleo, INC. | $1,489.16 | 2019 | |
| Biodelivery Sciences International, INC. | $967.72 | 2019-2020 | |
| Boston Scientific Corporation | $219.34 | 2020-2023 | |
| Collegium Pharmaceutical, INC. | $199.41 | 2019-2024 | Belbuca, Xtampza |
| Inari Medical, INC. | $189.02 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Spr Therapeutics, INC | $145.73 | 2021-2024 | Sprint Pns System |
| Stryker Corporation | $140.95 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Becton, Dickinson and Company | $131.16 | 2024 | Hemosphere |
| Abbott Laboratories | $123.05 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $81.68 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $71.00 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.36 | 2019-2020 | |
| Si-Bone, INC. | $63.90 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $37.52 | 2024-2025 | Qutenza |
| Pfizer INC. | $35.54 | 2019 | |
| Forte Bio-Pharma LLC | $35.33 | 2019-2022 | |
| Mdd US Operations, LLC | $32.87 | 2019 | |
| Lilly USA, LLC | $32.37 | 2021-2022 | |
| Chiesi USA, INC. | $21.61 | 2023 | Kengreal, Cleviprex |
| Eagle Pharmaceuticals, INC. | $21.29 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $18.22 | 2024 | Exparel |
| Kowa Pharmaceuticals America, INC. | $17.89 | 2023 | Seglentis |
| Abbvie INC. | $14.90 | 2021 | |
| Horizon Therapeutics Plc | $14.05 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.